Pancreatic cancer was almost invincible. A new targeted therapy has just doubled survival

Daraxonrasib nearly doubled median overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial, from 6.7 months to 13.2 months.

The multi-RAS inhibitor also improved progression-free survival and objective response rates versus standard chemotherapy.

The results, presented at ASCO, strengthen evidence that KRAS-targeted therapy could offer a new option in a disease with few effective second-line treatments.

Researchers are now testing combination approaches, though earlier studies noted significant side effects.